Information Provided By:
Fly News Breaks for October 19, 2015
MRTX
Oct 19, 2015 | 05:36 EDT
Barclays analyst Jonathan Eckard started shares of Mirati Therapeutics with an Overweight rating and $50 price target. The company is well positioned in the growing migration toward "personalized" cancer therapy, Eckard tells investors in a research note.
News For MRTX From the Last 2 Days
There are no results for your query MRTX